Health Affairs, 25, no. 2 (2006): 394-404 doi: 10.1377/hlthaff.25.2.394 © 2006 by Project HOPE	New Online   New Issue: China & India   Obesity In China   Pay Cuts For Medicare Docs   Access To Care Woes

This Article Full Text (HTML) Reprint (PDF) Submit a response to this article Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services E-mail this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Alert me to new issues of the journal Add to My Personal Archive Download to Citation Manager Reprints & Permissions Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (2) Citing Articles via Google Scholar Google Scholar Articles by Manheim, B. S. Articles by Dow, K. J. Search for Related Content PubMed Articles by Manheim, B. S., Jr. Articles by Dow, K. J. Related Collections Business Of Health Legal/Regulatory Issues Pharmaceuticals Research And Technology

Biotech Industry

‘Follow-On Biologics’: Ensuring Continued Innovation In The Biotechnology Industry

Congress adopted legislation in 1984 to encourage pharmaceutical companies to develop new drugs, while simultaneously allowing competitors to bring cheaper generic versions to market. More than twenty years later, Congress may be faced with a similar balancing act for biologics. When Congress takes up this issue, it must focus on the substantial differences that exist between biologics and drugs. It should also evaluate the patent law, which is yielding increasingly narrow patents. If additional measures are not adopted in light of the intersection of these factors, then any legislation allowing for "follow-on" biologics could stifle development of new medicines from biotechnology.

                      What's this?

This article has been cited by other articles:

				J. E. Calfee and E. DuPre The Emerging Market Dynamics Of Targeted Therapeutics Health Aff., September 1, 2006; 25(5): 1302 - 1308. [Abstract] [Full Text] [PDF]

				J. B. Watkins, S. R. Choudhury, E. Wong, and S. D. Sullivan Managing Biotechnology In A Network-Model Health Plan: A U.S. Private Payer Perspective Health Aff., September 1, 2006; 25(5): 1347 - 1352. [Abstract] [Full Text] [PDF]